Adagene Inc.
| NASDAQ: ADAG | Healthcare / Biotechnology / China |
| 1.29 | -0.0400 | -3.01% | Vol 7.17K | 1Y Perf -2.92% |
| Sep 22nd, 2023 16:00 DELAYED |
| BID | 1.23 | ASK | 1.48 | ||
| Open | 1.33 | Previous Close | 1.33 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 12.67 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 882.17 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★★ 50.54 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 32.50 | Earnings Rating | — | |
| Market Cap | 55.80M | Earnings Date | 30th Mar 2023 | |
| Alpha | -0.08 | Standard Deviation | 0.18 | |
| Beta | 0.17 |
Today's Price Range 1.291.35 | 52W Range 0.90002.10 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -8.51% | ||
| 1 Month | 4.88% | ||
| 3 Months | -4.44% | ||
| 6 Months | -15.13% | ||
| 1 Year | -2.92% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | -60.33 | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | -45.07 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -51.56 | |||
Return on invested Capital Q | - | |||
Return on invested Capital Y | -20.04 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.90 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.80 | ||||
| 0.62 | ||||
| 19.70 | ||||
| - | ||||
| -1.10 | ||||
| -1.00 | ||||
| 0.62 | ||||
| 2.60 | ||||
| -81 560 700.00 | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 3.00 | ||||
| 3.10 | ||||
| 0.08 | ||||
| 0.15 | ||||
| -211.80 | ||||
| Leverage Ratio | 1.60 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -635.70 | ||||
| -635.70 | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 3.92M | ||||
| 0.09 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | - |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 7.17K |
| Shares Outstanding | 43.25K |
| Shares Float | 14.79M |
| Trades Count | 49 |
| Dollar Volume | 9.41K |
| Avg. Volume | 13.37K |
| Avg. Weekly Volume | 5.96K |
| Avg. Monthly Volume | 9.20K |
| Avg. Quarterly Volume | 24.97K |
Adagene Inc. (NASDAQ: ADAG) stock closed at 1.29 per share at the end of the most recent trading day (a -3.01% change compared to the prior day closing price) with a volume of 7.17K shares and market capitalization of 55.80M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 198 people. Adagene Inc. CEO is Peter Luo.
The one-year performance of Adagene Inc. stock is -2.92%, while year-to-date (YTD) performance is -2.64%. ADAG stock has a five-year performance of %. Its 52-week range is between 0.9 and 2.1, which gives ADAG stock a 52-week price range ratio of 32.50%
Adagene Inc. currently has a PE ratio of -0.80, a price-to-book (PB) ratio of 0.62, a price-to-sale (PS) ratio of 19.70, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -45.07%, a ROC of -51.56% and a ROE of -60.33%. The company’s profit margin is -%, its EBITDA margin is -635.70%, and its revenue ttm is $3.92 Million , which makes it $0.09 revenue per share.
Of the last four earnings reports from Adagene Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Adagene Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Adagene Inc. is Strong Buy (1), with a target price of $12.67, which is +882.17% compared to the current price. The earnings rating for Adagene Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Adagene Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Adagene Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 36.77, ATR14 : 0.10, CCI20 : -24.66, Chaikin Money Flow : -0.11, MACD : 0.01, Money Flow Index : 49.98, ROC : -2.27, RSI : 44.15, STOCH (14,3) : 0.00, STOCH RSI : 0.00, UO : 40.97, Williams %R : -100.00), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Adagene Inc. in the last 12-months were:
Adagene Inc.
Adagene Inc is a clinical-stage immunotherapy company focused on the design and discovery of antibodies for the treatment of cancer.
CEO: Peter Luo
Telephone: +86 51287773632
Address: No. 218, Xinghu Street, Suzhou Industrial Park, Suzhou 25125, , CN
Number of employees: 198
